

**SAMPLE IMMUNOHISTOCHEMISTRY – EGFR REPORT**

**DIAGNOSIS:**

**ABC Hospital A07-12345**

Soft tissue, left supraclavicular mass, needle biopsy: Metastatic adenocarcinoma consistent with colorectal primary, **positive** for EGFR expression by immunohistochemistry.

**SPECIMEN INFORMATION:**


A1 = A07-12345, 1 block

**RECEIVED FOR THE FOLLOWING:**

EGFR immunostain

**IMMUNOHISTOCHEMICAL FINDINGS:**

Tissue sections (along with appropriate positive control) are incubated with the following antibody. Localization is via a biotin-free, polymer-based immunoperoxidase technique according to an optimized protocol. The controls are reviewed for appropriate positive and negative reactivity and found to be satisfactory.



Block A07-12345 (Surgery Date: 01/05/2007) - Supraclavicular mass (PP2007XXXXX A1)

Target Population: Tumor

Antibodies To	Clone	Result
EGFR (S)	31G7	Positive [60%]

**\*\*\*ELECTRONICALLY SIGNED\*\*\***

**Patricia Kandalaf, M.D.**  
**Pathologist**

*In compliance with CMS regulations, the pathologist's signature on this report indicates that the case has been personally reviewed, and the diagnosis made or confirmed by the Pathologist.*

*NOTE: Some of the tests reported here may have been developed and performance characteristics determined by PhenoPath Laboratories. They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). However, the FDA has determined that such clearance or approval is not necessary. Pursuant to the requirements of CLIA, this laboratory has established and verified the accuracy and precision of all tests, and additional information about these tests is available upon request. PhenoPath Laboratories is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.*